Cell & Gene Therapy CDMO Services
Cell and gene therapy programs carry a different kind of manufacturing pressure.
The product is often complex, sensitive, high-value, and difficult to replace. A single delay can affect clinical timelines. A single assay weakness can slow release. A single cold chain error can compromise material. A single process change can create comparability questions that reach across manufacturing, analytics, regulatory CMC, and clinical supply.
Cell and gene therapy CDMO services support programs that require specialized production, testing, documentation, and logistics. These programs include viral vector manufacturing, plasmid DNA supply, cell therapy manufacturing, ex vivo modification workflows, in vivo gene therapy programs, genome editing materials, advanced therapy medicinal products, and supporting biologic components.
CDMO Network helps cell and gene therapy developers connect the major pieces of the CMC path: plasmid production, viral vector manufacturing, cell processing, analytical testing, potency strategy, sterile drug product support, GMP readiness, tech transfer, regulatory documentation, and cold chain logistics.
The work needs more than available capacity.
It needs orchestration.
Cell and gene therapy programs often depend on multiple linked materials and vendors. A plasmid supplier feeds a vector CDMO. A vector batch feeds a cell therapy process. A potency lab controls release. A fill-finish partner handles final presentation. A logistics provider protects frozen or cryogenic shipment. A regulatory team explains the system. If one piece slips, the whole program absorbs the shock.
This industry rewards teams that build the chain before the chain is tested.
Built for advanced therapy complexity
Cell and gene therapy development does not follow a simple biologics template.
A monoclonal antibody program can often lean on platform experience. Cell and gene therapy programs need more custom planning. The process, product, assay system, logistics model, and regulatory package all depend on the therapy type.
An in vivo AAV gene therapy needs vector production, capsid quality, genome integrity, functional potency, residual impurity control, stability, sterile presentation, and cold chain. An ex vivo cell therapy needs cell sourcing, activation, transduction or editing, expansion, harvest, formulation, cryopreservation, chain of identity, and release testing. A lentiviral vector program needs plasmid input control, producer system control, infectivity, potency, residual host-cell DNA, residual plasmid, and storage strategy. A genome editing program needs nucleases, guide RNAs, donor templates, delivery systems, off-target awareness, and functional testing.
The Network supports these programs by matching the technical route to the therapy design.
Not every advanced therapy needs the same CDMO.
Not every CDMO that says “cell and gene therapy” can carry the same risk.
Viral vector manufacturing
Viral vectors sit at the center of many gene therapy programs.
AAV, lentiviral vectors, adenoviral vectors, HSV-based vectors, oncolytic viruses, and other vector platforms require specialized manufacturing and analytical systems. The process usually includes plasmid or helper inputs, producer cells, transfection or infection, harvest, clarification, nuclease treatment, purification, concentration, buffer exchange, sterile filtration where appropriate, and frozen or refrigerated storage.
The hard part is not only making particles.
The hard part is making functional material with controlled impurities.
A vector batch needs more than genome titre. It needs a data package that addresses particle quality, functional titre, infectivity, potency, residual plasmid, residual host-cell DNA, host-cell protein, aggregation, safety-related testing, and stability.
A simple vector equation helps clarify the issue:
useful vector output = physical output × functional integrity × impurity control
If physical output rises but functional integrity drops, the process has not improved.
If yield improves but residual impurities increase, the program gains a new problem.
Vector manufacturing needs CDMO partners that understand both biology and release strategy.
Plasmid DNA and critical starting materials
Plasmids often determine the pace of a gene therapy program.
They support viral vector production, mRNA templates, genome editing systems, vaccine platforms, and direct nucleic-acid products. If plasmids arrive late, vector manufacturing slips. If topology fails, downstream performance suffers. If endotoxin is high, purification and release become harder. If sequence confirmation is weak, confidence drops.
Strong plasmid support includes strain selection, fermentation, harvest, lysis, purification, topology control, supercoiled percentage, endotoxin reduction, residual RNA removal, residual host-cell DNA control, sequence confirmation, storage, and documentation.
For vector programs, plasmid quality affects more than one intermediate. It can affect transfection performance, vector productivity, residual impurity burden, and batch consistency.
Cell and gene therapy teams should treat plasmids as strategic materials, not commodity inputs.
The starting material sets the tone for the therapy.
Cell therapy manufacturing and process control
Cell therapy manufacturing adds a human or cellular starting material to the CMC challenge.
Programs can involve autologous cells, allogeneic cells, immune cells, stem-cell-derived products, engineered cells, edited cells, or other cell-based platforms. The process can include collection, cell receipt, selection, activation, gene modification, expansion, washing, harvest, formulation, cryopreservation, storage, shipment, and administration-site coordination.
The control system must protect identity, purity, viability, potency, sterility, cell phenotype, vector copy number where relevant, editing outcome where relevant, and product consistency.
Autologous programs bring chain-of-identity pressure. Allogeneic programs bring scale and batch-consistency pressure. Edited cell programs bring editing efficiency, off-target, genotype, phenotype, and functional questions. Cryopreserved products bring thawing, post-thaw viability, potency, and clinical-site handling concerns.
Cell therapy manufacturing does not tolerate vague logistics.
The product and the patient can become tightly linked.
The manufacturing system must respect that link.
Potency and functional assay strategy
Potency creates one of the hardest problems in cell and gene therapy.
A therapy can look acceptable by identity or particle count and still fail to show meaningful biological function. Potency strategy needs to connect the product to its intended mechanism.
For AAV products, potency can involve transgene expression, cell-based activity, infectivity, or biological function. For lentiviral vectors, potency can involve infectious titre, transduction efficiency, expression, or downstream functional readouts. For cell therapies, potency can involve killing activity, cytokine production, differentiation capacity, viability-adjusted function, marker expression, proliferation, or mechanism-specific assays. For genome editing products, potency can involve editing efficiency, corrected expression, pathway restoration, or functional rescue.
Potency assays must also mature over time. Early assays can support development. Later assays must support release, comparability, stability, and regulatory review.
The Network supports potency strategy as a product-design issue, not only an assay-development task.
The question is not “Which assay can run?”
The question is “Which assay proves this therapy still does what it was built to do?”
Analytics for advanced therapies
Cell and gene therapy analytics require a broad method set.
Relevant testing can include genome titre, particle titre, infectious titre, vector copy number, transduction efficiency, editing efficiency, residual plasmid, residual host-cell DNA, host-cell protein, residual nuclease, replication-competent virus testing where relevant, sterility coordination, endotoxin, mycoplasma, viability, identity, phenotype, potency, purity, impurities, adventitious agent testing, stability, and final presentation testing.
For cell products, flow cytometry often becomes central. For vector products, qPCR, ddPCR, infectivity assays, ELISA, capillary electrophoresis, chromatography, and cell-based potency assays all matter. For plasmids and nucleic acids, sequence, topology, purity, residual RNA, endotoxin, and storage behavior matter.
Analytics need to carry multiple decisions:
Can the batch release?
Can the product remain stable?
Can the process change?
Can the method transfer?
Can the agency understand the control system?
Advanced therapy analytics should not create a pile of unrelated tests.
They should create a map of product function, safety, and consistency.
Fill-finish, cryopreservation, and final presentation
Cell and gene therapy products often need specialized final handling.
Viral vectors can require sterile filtration, vial filling, frozen storage, ultra-low storage, or cryogenic conditions. Cell therapy products can require formulation, cryopreservation, controlled-rate freezing, cryobags, vials, thaw instructions, infusion preparation, and chain-of-identity controls. Some advanced therapies require short hold times, rapid release workflows, or site-specific administration planning.
Final presentation risks include particle formation, loss of infectivity, activity loss, adsorption to surfaces, cryoprotectant effects, container interaction, thawing variability, post-thaw viability decline, and in-use limitations.
A frozen product is not finished when it enters the freezer.
It still needs evidence for storage, shipment, thaw, preparation, and use.
Cell and gene therapy drug product work must protect the therapy at its most vulnerable points: after manufacture, during movement, and immediately before administration.
Regulatory CMC for cell and gene therapy
Regulatory CMC for advanced therapies needs clarity.
The filing must explain the product, materials, process, controls, assays, specifications, comparability strategy, safety testing, stability, storage, chain of custody where relevant, and clinical-use handling. A weak narrative creates questions quickly because these products carry high complexity.
Support can include IND, IMPD, CTA, BLA, MAA, agency briefing packages, deficiency responses, comparability packages, and lifecycle documentation.
Cell and gene therapy filings often need extra attention to:
- starting material control
- vector or cell manufacturing process
- potency assay rationale
- residual impurity strategy
- safety-related testing
- comparability after process changes
- stability and frozen storage
- chain of identity and chain of custody
- final presentation and administration handling
The strongest regulatory package does not hide complexity.
It organizes complexity so reviewers can follow the control logic.
Quality systems and GMP readiness
Cell and gene therapy GMP readiness requires practical control before manufacturing begins.
That includes quality agreements, batch records, raw material release, supplier qualification, chain of identity, chain of custody, deviation pathways, change control, OOS support, data integrity, environmental monitoring where relevant, aseptic processing review, release procedures, stability protocols, and documentation flow.
Advanced therapy programs often work across multiple specialized partners. A plasmid supplier, vector manufacturer, cell processor, testing lab, fill-finish provider, logistics vendor, and clinical site can all affect product quality.
Quality systems must make ownership visible.
Who owns the starting material review?
Who confirms chain of identity?
Who approves vector release?
Who controls cryoshipper records?
Who evaluates an excursion?
Who determines regulatory impact after a process adjustment?
A program should answer these questions before the batch exists.
Zell- und Gentherapie verlangt mehr als Kapazität. Sie verlangt Kontrolle über biologische Funktion, sensible Materialien, kurze Zeitfenster, tiefgekühlte Lieferketten und anspruchsvolle CMC-Nachweise. Die besten Programme improvisieren nicht; sie bauen eine präzise Kette aus Plasmid, Vektor, Zelle, Analyse, Qualität und Logistik. CDMO Network hilft, diese Kette klar, belastbar und entwicklungsfähig zu machen.
Cell therapy program support
Cell therapy programs need integrated manufacturing, testing, logistics, and quality support.
Core areas include cell sourcing, cell selection, activation, transduction, editing, expansion, washing, formulation, cryopreservation, storage, release testing, phenotype analysis, viability, potency, sterility coordination, endotoxin, mycoplasma, chain of identity, and clinical-site preparation.
Autologous cell therapy programs demand patient-linked traceability and fast operational coordination. Allogeneic programs demand batch consistency, scale, banking strategy, and broader distribution readiness.
The CMC system must fit the therapy model.
An autologous product and an allogeneic product do not create the same manufacturing problem.
Gene therapy program support
Gene therapy programs often depend on vector manufacturing and functional analytics.
Support areas include plasmid production, viral vector production, producer cell systems, upstream production, downstream purification, residual impurity testing, potency assays, infectivity, stability, fill-finish, frozen storage, and regulatory CMC documentation.
AAV programs often focus on capsid quality, genome titre, empty/full profile, potency, residual impurities, and stability. Lentiviral programs often focus on infectious titre, transduction efficiency, vector copy number, residual impurities, and frozen handling. Other vector systems bring their own safety and process questions.
Gene therapy CDMO support should keep the therapeutic function visible.
A delivery system has to deliver.
Genome editing and hybrid advanced therapy support
Genome editing programs can sit between gene therapy, cell therapy, nucleic-acid manufacturing, and biologics.
Support can include guide RNA production, nuclease production, donor template manufacturing, plasmids, mRNA templates, viral delivery systems, nonviral delivery systems, edited cell processing, editing efficiency assays, off-target awareness, functional assays, and release strategy.
Hybrid programs create coordination risk because no single legacy CDMO category fully covers the work. The manufacturing and analytical model must follow the therapy design.
For these programs, the first job is to define the product architecture.
What is the therapeutic material?
What is the delivery system?
What is the critical starting material?
What must release?
What must remain stable?
What must be comparable after change?
When those answers stay loose, the CDMO search becomes messy.
Cold chain and clinical logistics
Cell and gene therapy logistics can decide whether a product remains usable.
Programs need cold chain planning, frozen storage, ultra-low storage, cryogenic handling where relevant, validated shippers, chain of custody, chain of identity, temperature monitoring, clinical-site coordination, returns, reconciliation, and excursion response.
Cell products can require tight timing from collection to manufacturing to administration. Viral vectors can require frozen or ultra-low shipment. Some products need thawing instructions, post-thaw hold times, infusion preparation, or restricted handling windows.
The logistics plan must match the product’s biological limits.
A therapy can pass release and still fail operationally if the clinical site cannot receive, store, thaw, prepare, or administer it correctly.
Industry Fit
Cell and gene therapy developers use this support when they need to:
- manufacture viral vectors, plasmids, or cell-based products
- move from research workflows into GMP manufacturing
- develop potency, infectivity, editing, or phenotype assays
- manage frozen, ultra-low, or cryogenic logistics
- prepare IND, IMPD, CTA, BLA, MAA, or agency-response packages
- qualify suppliers for plasmids, vectors, cells, reagents, and critical materials
- transfer processes between development labs, CDMOs, and clinical sites
- build release, stability, comparability, and regulatory CMC packages
- coordinate multiple specialized partners under one program plan
This industry page fits advanced therapy developers that need more than one vendor and cannot afford disconnected execution.
Capability areas for cell and gene therapy CDMO services
Cell and gene therapy programs use capabilities across:
- plasmid DNA manufacturing and critical starting material control
- AAV, lentiviral, adenoviral, HSV, and oncolytic vector manufacturing
- cell therapy processing, expansion, activation, modification, and cryopreservation
- genome editing material support
- upstream production and downstream purification
- potency, infectivity, activity, phenotype, and editing assays
- qPCR, ddPCR, flow cytometry, ELISA, chromatography, and cell-based testing
- residual impurity testing and safety-related assays
- sterile fill-finish, frozen drug product, and cryogenic handling
- stability, post-thaw, in-use, and clinical handling studies
- GMP readiness, QMS support, and supplier qualification
- regulatory CMC, agency response, and comparability support
- cold chain, chain of custody, chain of identity, and clinical logistics
The exact structure depends on whether the program is vector-based, cell-based, editing-based, or a hybrid advanced therapy.
Zell- und Gentherapie-CDMO-Services verbinden Plasmidherstellung, virale Vektoren, Zellprozessierung, Potenzanalytik, funktionelle Tests, GMP-Qualität, Kryokonservierung, Stabilität, Logistik und regulatorische CMC-Dokumentation. Für AAV, Lentiviren, editierte Zellen, autologe Therapien, allogene Plattformen oder hybride Genome-Editing-Programme ändert sich die Kontrollstrategie. Gute Entwicklung beginnt nicht mit einer Lieferantenliste. Sie beginnt mit der Frage, welche biologische Funktion geschützt, gemessen und bis zur Anwendung erhalten werden muss.
Requirements for high-quality cell and gene therapy CDMO services
A robust CDMO strategy for cell and gene therapy begins with clearly defined therapy architecture.
This includes product type, starting materials, delivery system, manufacturing process, assay requirements, potency framework, release strategy, stability profile, chain of identity, logistics model, regulatory milestones, and clinical-use conditions—established prior to CDMO selection.
Comprehensive support spans plasmid manufacturing, viral vector production, cell processing, genome editing materials, potency assay development, infectivity testing, phenotypic analysis, residual impurity testing, GMP manufacturing, sterile fill-finish, cryopreservation, cold-chain logistics, analytical development, QC testing, regulatory CMC, quality systems, supplier qualification, tech transfer, comparability, and clinical supply coordination.
Requirements vary by modality:
- Autologous cell therapies require strict traceability, rapid turnaround, chain of identity control, and clinical-site coordination.
- Allogeneic cell therapies require robust cell banking, scalable manufacturing, batch consistency, and distribution planning.
- Gene therapies require high vector quality, functional analytics, impurity control, cold storage, and regulatory clarity.
- Genome editing programs require precise control of editing components, delivery systems, functional outcomes, and assay strategy.
Treating cell and gene therapy as a single CDMO category is a common error. These are interconnected biological systems, each requiring a tailored manufacturing, testing, quality, and logistics model.
CDMO Network is positioned to support this full spectrum of requirements.
Email our team at info@cdmonetwork.com